Santen Pharmaceutical Co Ltd - Company Profile
Powered by
All the data and insights you need on Santen Pharmaceutical Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Santen Pharmaceutical Co Ltd Strategy Report
- Understand Santen Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Santen Pharmaceutical Catalyst Calendar
Proactively evaluate Santen Pharmaceutical Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Santen Pharmaceutical Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
30 Jun 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
31 Jan 2020 | Phase II Trial Completion | Santen Pharmaceutical Co Ltd; Singapore Eye Research Institute | 4536 | undisclosed vascular endothelial growth factor | Metabolic Disorders | Diabetic Macular Edema | Clinical Trial Registry |
31 Dec 2019 | Phase III Trial Completion | Keystone Research; Santen Pharmaceutical Co Ltd | 4536 | omidenepag isopropyl | Ophthalmology | Glaucoma; Ocular Hypertension | Clinical Trial Registry |
01 Dec 2019 | Phase II Trial Completion | Labcorp Drug Development; Santen Pharmaceutical Co Ltd | 4536 | carotuximab | Ophthalmology | Age Related Macular Degeneration; Choroidal Neovascularization; Polypoidal Choroidal Vasculopathy; Wet (Neovascular / Exudative) Macular Degeneration | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer